Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2024, Vol. 29 ›› Issue (3): 316-327.doi: 10.12092/j.issn.1009-2501.2024.03.010

Previous Articles     Next Articles

The application of positron emission tomography in the research and development of central nervous system drugs

LI Size1, HUANG Qi2,3, WU Xiaojie1 , WANG Shaonan4, GUAN Yihui2,3, XIE Fang2,3, ZHANG Jing1,5   

  1. 1Phase I Clinical Research Center, Huashan Hospital, Fudan University, Shanghai 200040, China; 2Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai 200235, China; 3National Center for Neurological Disorders (Huashan), Shanghai 200040, China; 4Translational Medicine & Clinical Pharmacology, Boehringer Ingelheim, The Chinese Market, Shanghai 200040, China; 5Institue of Antibiotics, Huashan Hospital, Fudan University, Shanghai 200040, China
  • Received:2023-05-25 Revised:2024-01-04 Online:2024-03-26 Published:2024-02-29

PDF (PC)

103

Abstract:

Positron emission tomography (PET) now plays an important role in the research and development (R&D) of central nervous system (CNS) drugs. PET could characterize the biodistribution, pharmacokinetics, and receptor binding of CNS drugs quantitatively. The present review summarized the quantitative methods of PET used in the pharmacokinetics and receptor occupancy analysis of CNS drugs. Moreover, the present review listed various applications of PET supporting R&D of CNS drugs, which could provide a new direction for the R&D of CNS drugs.

Key words: positron emission tomography, central nervous system, the research and development of new drugs, pharmacokinetics, receptor occupancy

CLC Number: